Insider Selling: Vor Biopharma Inc. (NYSE:VOR) Insider Sells $12,917.50 in Stock

Vor Biopharma Inc. (NYSE:VOR) insider Eyal C. Attar sold 10,334 shares of the firm’s stock in a transaction on Friday, December 27th. The stock was sold at an average price of $1.25, for a total value of $12,917.50. Following the transaction, the insider now owns 81,439 shares of the company’s stock, valued at approximately $101,798.75. This represents a 11.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Vor Biopharma Stock Up 0.9 %

Shares of NYSE:VOR opened at $1.12 on Friday. Vor Biopharma Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $3.14. The stock has a market cap of $76.91 million, a price-to-earnings ratio of -0.68 and a beta of -0.37. The firm’s 50 day moving average price is $0.89 and its 200 day moving average price is $0.89.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40). On average, equities analysts anticipate that Vor Biopharma Inc. will post -1.55 EPS for the current year.

Institutional Trading of Vor Biopharma

Institutional investors have recently bought and sold shares of the business. Hsbc Holdings PLC raised its position in shares of Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after acquiring an additional 31,333 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Vor Biopharma during the second quarter worth approximately $53,000. Rosalind Advisors Inc. purchased a new stake in shares of Vor Biopharma during the 3rd quarter worth approximately $54,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Vor Biopharma in the 2nd quarter valued at $63,000. Finally, Acadian Asset Management LLC grew its position in shares of Vor Biopharma by 51.4% in the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after buying an additional 27,597 shares during the last quarter. 97.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

VOR has been the topic of several research reports. JMP Securities reissued a “market outperform” rating and set a $12.00 target price on shares of Vor Biopharma in a research note on Tuesday, December 10th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Vor Biopharma in a research note on Monday, December 9th. Robert W. Baird decreased their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Finally, HC Wainwright restated a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $11.36.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.